Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- Check5 days agoChange Detected- Revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedHypopharynx cancer and Oropharynx cancer were added to the Conditions list, and a Genetic and Rare Diseases Information Center resource was added under Resources.SummaryDifference0.2%

- Check34 days agoChange DetectedAdded site revision note: Revision v3.4.2. Removed older notices (Revision v3.4.1) and the funding-status message; no trial data or core page content was altered.SummaryDifference0.4%

- Check41 days agoChange DetectedThe study status was updated to Completed with revised completion and enrollment details, and a government funding/operating-status notice was added.SummaryDifference0.8%

- Check48 days agoChange DetectedAdded a 'Show glossary' option and updated QC metadata to 'Last Update Submitted that Met QC Criteria' with revision 'v3.4.0'; removed the older QC label variants and the 'Revision: v3.3.4' label.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision update from v3.3.3 to v3.3.4. No substantive changes to study details or page content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.